Karyopharm Therapeutics
Andy Holton has extensive experience in the pharmaceutical industry, with roles ranging from District Sales Manager to Vice President of Market Access. Throughout their career, Andy has been involved in launching new medications, developing national sales strategies, and managing teams of sales associates. Holton's background also includes positions in marketing research and oncology sales. Andy holds a degree from The University of Kansas and attended Bishop Ward High School.
This person is not in any offices
Karyopharm Therapeutics
13 followers
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).